Parecoxib is a water-soluble and injectable prodrug of valdecoxib. It is marketed as Dynastat in the European Union. Parecoxib is a COX2 selective inhibitor in the same category as celecoxib (Celebrex) and rofecoxib (Vioxx). As it is injectable, it can be used perioperatively when patients are unable to take oral medications. It is approved through much of Europe for short term perioperative pain control much in the same way ketorolac (Toradol) is used in the United States. In 2005, the U.S. Food and Drug Administration (FDA) issued a letter of non-approval for parecoxib in the United States.
Used for short term perioperative pain control.
Hepatic. Metabolized primarily via CYP3A4 and 2C9 to valdecoxib and propionic acid.
(R)-warfarin The risk or severity of bleeding and hemorrhage can be increased when Parecoxib is combined with (R)-warfarin.
(S)-Warfarin The metabolism of (S)-Warfarin can be decreased when combined with Parecoxib.
1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid The risk or severity of renal failure, hyperkalemia, and hypertension can be increased when Parecoxib is combined with 1-(3-Mercapto-2-Methyl-Propionyl)-Pyrrolidine-2-Carboxylic Acid.
1-benzylimidazole The risk or severity of hypertension can be increased when 1-benzylimidazole is combined with Parecoxib.
2,5-Dimethoxy-4-ethylamphetamine The risk or severity of hypertension can be increased when 2,5-Dimethoxy-4-ethylamphetamine is combined with Parecoxib.
2,5-Dimethoxy-4-ethylthioamphetamine The risk or severity of hypertension can be increased when Parecoxib is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.
3,5-diiodothyropropionic acid The metabolism of 3,5-diiodothyropropionic acid can be decreased when combined with Parecoxib.
4-Bromo-2,5-dimethoxyamphetamine The risk or severity of hypertension can be increased when 4-Bromo-2,5-dimethoxyamphetamine is combined with Parecoxib.
4-hydroxycoumarin The metabolism of 4-hydroxycoumarin can be decreased when combined with Parecoxib.
4-Methoxyamphetamine The risk or severity of hypertension can be increased when 4-Methoxyamphetamine is combined with Parecoxib.